Impacting Patient Care Through Novel Drug Discovery
SiNOPSEE Therapeutics is a bio-pharmaceutical company focused on the discovery, design, and development of small molecular weight compounds for the treatment of chronic diseases. It was founded in 2017 by a group of scientists from the Agency for Science, Technology & Research (A*STAR), in Singapore.
SiNOPSEE Therapeutics is led by a team deeply rooted scientifically and passionate in novel drug discovery research. We have a long-standing prominent network globally with Key Opinion Leaders (KOL) and industrial experts. Our scientific advisors are highly regarded for successfully rolling novel molecules which have significantly contributed towards patient healthcare. As a dedicated team, we envision to impact patient-care through discovery, research, and development of novel therapeutics
Scientific Advisory Board
Experimental Therapeutics Centre (ETC)
and Drug Discovery & Development (D3)
Department of Biochemistry,
University of Cambridge
and Director Emeritus,
Prof Brien Holden Eye Research Centre
SiNOPSEE's founders have co-developed a novel class of lead molecules against abnormal blood vessel formation which drives disease progression in certain opthalmic conditions and cancer. First in the series, these novel, highly selective and potent molecules (in the developmental pipeline) are inhibitors against platelet-derived growth factor receptor (PDGFR) and vesicular endothelial growth factor receptor (VEGFR) families, for the treatment of wet-AMD (age-related macular degeneration).
SiNOPSEE's small molecule inhibitors were identified using proprietary screening technology of the Institute of Molecular and Cell Biology (A*STAR) & Bioprocessing Technology Institute (A*STAR). The molecules were optimized for potency and selectivity guided by in-silico molecular modeling carried out using protocols developed at the Bioinformatics Institute (A*STAR). Our lead molecules exhibit good potency and selectivity and show excellent promise in in-vitro (cell lines), ex-vivo (organoid) & in-vivo (rodent) models. With a co-development partner, SiNOPSEE is currently developing formulations that can be used to administer the therapeutic agent as topical eye drops.
AMD is the leading cause of irreversible blindness in people ≥ 50 years of age and ranks third among the global causes of visual impairment with a prevalence of 8.7% with wet or neovascular AMD (Late stage AMD) accounting for ~10% of all AMD patients. It is characterized by the formation of new blood vessels emanating from the chorio-capillaries (choroidal neovascularization or CNV) that leak into the retina and vitreous cavity. Left untreated, the disease progresses rapidly to cause loss of visual acuity within a few months.
VEGF is a validated therapeutic target for anti-angiogenic therapy. Current standard-of-care treatment includes FDA approved anti-VEGF inhibitors/antibodies Aflibercept (Eylea), Ranibizumab (Lucentis) and Bevacizumab (Avastin). However, anti-VEGF therapy is expensive and patient compliance is low as the antibodies are administered once every three months by direct injection into the eye. Moreover, a significant number of patients are refractory to the current therapies. The high treatment costs, with a large number of patients needing injections over a long period, places a strain on the health-care system. Our goal is to develop novel therapeutic agents for wet-AMD that overcome the current limitations.
SiNOPSEE Therapeutics is currently seeking seed funding for the development of its lead molecules to a preclinical stage. Next round of funding will be sought for early-stage clinical trials. The exit strategy is to subsequently out-license the compound(s) to major pharmaceutical companies for advanced clinical trials and commercialization. Out-licensing deals and transaction value in this arena presents high significance and potential, thereby promising a substantial return on investment.
The global market opportunity for wet AMD was ~$8 billion in 2016 and the disease prevalence is expected to increase by 50% by 2020.
Current therapy requires intra-ocular injection of antibodies. Hence, the market projection of SiNOPSEE's molecules with topical eye drop administration is compelling.
Out-licensing deals and transaction value in this arena presents high significance and potential.
More broadly, PDGFR/VEGFR as therapeutic targets can expand the market further to include cancer, diabetes, and other major pathologies.
For more information about SiNOPSEE Therapeutics and investment opportunities please send an e-mail at firstname.lastname@example.org
GET IN TOUCH
A*STARTCentral, #05-03, 79 Ayer Rajah Crescent, Singapore 139955